Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab
| Autor: | Walo-Delgado, Paulette Esperanza, Monreal, Enric, Medina, Silvia, Quintana, Ester, Sainz de la Maza, Susana, Fernández-Velasco, José Ignacio, Lapuente, Paloma, Comabella, Manuel, Ramió-Torrentà, Lluís, Montalban, Xavier, Midaglia, Luciana, Villarrubia, Noelia, Carrasco-Sayalero, Angela, Rodríguez-Martín, Eulalia, Roldán, Ernesto, Meca-Lallana, José, Alvarez-Lafuente, Roberto, Masjuan, Jaime, Costa-Frossard, Lucienne, Villar, Luisa M, Universitat Autònoma de Barcelona |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Walo-Delgado PE, Medina S, Fernández-Velasco JI] Department of Immunology, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain. [Monreal E, Sainz de la Maza S] Department of Neurology, Ramón y Cajal University Hospital, IRYCIS, Red Española de Esclerosis Múltiple (REEM), Madrid, Spain. [Quintana E] Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Neurodegeneration and Neuroinflammation Research Group, Biomedical Research Institute (IDIBGI), Red Española de Esclerosis Múltiple (REEM), Girona, Spain. [Comabella M, Montalban X, Midaglia L] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Red Española de Esclerosis Múltiple (REEM), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
T-Lymphocytes Autoimmunity Other subheadings::Other subheadings::/drug therapy [Other subheadings] multiple sclerosis Gastroenterology Natalizumab Interquartile range alemtuzumab Immunology and Allergy Medicine Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Multiple Sclerosis::Multiple Sclerosis Relapsing-Remitting [DISEASES] Prospective cohort study Side effects Alemtuzumab Original Research B-Lymphocytes Autoimmunitat autoimmunity Middle Aged enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple recurrente-remitente [ENFERMEDADES] side effects disease modifying treatments Disease modifying treatments Female Immunosuppressive Agents medicine.drug Adult medicine.medical_specialty Cèl·lules B Immunology Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] Cells::Antibody-Producing Cells::B-Lymphocytes [ANATOMY] Multiple sclerosis Multiple Sclerosis Relapsing-Remitting Internal medicine Humans Adverse effect células::células productoras de anticuerpos::linfocitos B [ANATOMÍA] B cells business.industry biomarkers Odds ratio RC581-607 medicine.disease Immunologic diseases. Allergy business Esclerosi múltiple - Tractament CD8 Biomarkers |
| Zdroj: | Frontiers in Immunology Scientia Frontiers in Immunology, Vol 12 (2021) |
| Popis: | Células B; Alemtuzumab; Autoinmunidad Limfòcits B; Alemtuzumab; Autoimmunitat B cells; Alemtuzumab; Autoimmunity Objective: To explore if baseline blood lymphocyte profile could identify relapsing remitting multiple sclerosis (RRMS) patients at higher risk of developing secondary autoimmune adverse events (AIAEs) after alemtuzumab treatment. Methods: Multicenter prospective study including 57 RRMS patients treated with alemtuzumab followed for 3.25 [3.5-4.21] years, (median [interquartile range]). Blood samples were collected at baseline, and leukocyte subsets determined by flow cytometry. We had additional samples one year after the first cycle of alemtuzumab treatment in 39 cases. Results: Twenty-two patients (38.6%) developed AIAEs during follow-up. They had higher B-cell percentages at baseline (p=0.0014), being differences mainly due to plasmablasts/plasma cells (PB/PC, p=0.0011). Those with no AIAEs had higher percentages of CD4+ T cells (p=0.013), mainly due to terminally differentiated (TD) (p=0.034) and effector memory (EM) (p=0.031) phenotypes. AIAEs- patients also showed higher values of TNF-alpha-producing CD8+ T cells (p=0.029). The percentage of PB/PC was the best variable to differentiate both groups of patients. Baseline values >0.10% closely associated with higher AIAE risk (Odds ratio [OR]: 5.91, 95% CI: 1.83-19.10, p=0.004). When excluding the 12 patients with natalizumab, which decreases blood PB/PC percentages, being the last treatment before alemtuzumab, baseline PB/PC >0.1% even predicted more accurately the risk of AIAEs (OR: 11.67, 95% CI: 2.62-51.89, p=0.0007). The AIAEs+ group continued having high percentages of PB/PC after a year of alemtuzumab treatment (p=0.0058). Conclusions: A PB/PC percentage |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|